Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Clinical Evidence Aspiration Risk Evidence The clinical evidence regarding GLP-1 RA-associated aspiration risk has evolved from alarming case reports to more nuanced observational data
Phase 2 data showed up to 24.2% weight loss at 48 weeks
Given that retatrutide targets an additional receptor (glucagon) and has shown superior weight loss even to tirzepatide in cross-trial comparisons, Eli Lilly may price it at a premium
Common symptoms include: Mild redness Itching or warmth Swelling or firmness under the skin Tenderness or soreness A small raised bump Most reactions appear within hours to a few days after the injection and improve on their own
Crit Care (2023) 27(1):234
US$ 20.01
US$ 26.65
US$ 29.88
